Patients with certain driver mutations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC), show poor response to ICIs and may even develop HPD [13, 14]. Here, EGFR is linked to non-small cell lung carcinoma.